Skip to content

Tailoring obesity and type 2 diabetes management: Exploring the impact of ozempic/wegovy® on energy expenditure

Obesity | Diabetes | Body Composition | Energy Expenditure

Semaglutide (Ozempic/Wegovy®) seems promising at controlling appetite and reducing weight, but how it affects the way our bodies burn calories is still a debate. We are doing a study with 20 people who have obesity and type 2 diabetes. They will use semaglutide once weekly for 6 months, and we will evaluate how their bodies use energy in different situations, such as resting, exercising, eating, and sleeping. We will also explore body composition (e.g., muscle and fat) to determine if semaglutide can prevent the body from slowing down its energy use after weight loss. Our findings may contribute to the development of more personalized treatments, particularly for individuals who do not respond well to conventional treatments.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    18 to 50

Participation Criteria

Inclusion Criteria:
• Age: 18-50 years
• Obesity: body mass index (BMI=weight/height2) ≥30kg/m2 + elevated waist circumference (i.e., ≥102cm males, ≥88cm females)
• Type 2 diabetes: diagnosis ≥6 months + controlled blood sugar levels (HbA1c test < 9.0%)
• About to start using semaglutide subcutaneously at a dose of up to 2.4 mg per week for 6 months (per standard care decision/prescription) and willing to acquire the medication on their own
Exclusion Criteria:
• Weight ≥ 180 kg or history of metabolic and bariatric surgery
• Chronic diseases or medication use in the past 90 days with an impact on energy expenditure and body composition
• Advanced asthma, use of assisted breathing devices (e.g., inhalers, CPAP), or active smoking
• Regular use of medications to induce sleep or dipeptidyl peptidase-4 inhibitor medications (e.g., sitagliptin, saxagliptin, linagliptin, and alogliptin)
• Mental health symptoms that are not currently stabilized or use of medications
• Uncontrolled blood pressure (systolic ≥160 mmHg or diastolic ≥90 mmHg), or pacemaker
• Infections or recent hospitalization in the past 60 days
• Menopause, hormonal replacement therapy, pregnancy, or breast-feeding
• Not able or willing to: walk for 30 minutes; adhere to the diet menu inside the whole-room indirect calorimetry; stay in a closed environment
• Metal implants, amputation, or joint replacement devices

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Giovanna Bergamasco

[email protected]
null
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00149433